Quinoline antimalarials

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 2, 2001, Pages 185-209

  Egan, T J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Aminoquinoline; Antimalarial; Chloroquine; Malaria; Mechanism quinoline; Resistance

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; 8 AMINOQUINOLINE DERIVATIVE; ACRIDINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; CELL EXTRACT; CHLOROQUINE; HALOFANTRINE; HEMATIN; HEME; HEMOGLOBIN; HEMOZOIN; HISTIDINE; INSECTICIDE; IRON DERIVATIVE; MEFLOQUINE; PHENANTHRENE DERIVATIVE; PLASMEPSIN I; PLASMEPSIN II; PORPHYRIN DERIVATIVE; PRIMAQUINE; PROTOPORPHYRIN; PROTOZOAL PROTEIN; PYRONARIDINE; QUINIDINE; QUININE; QUINOLINE DERIVATIVE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WR 268568; WR 268858;

AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; CARDIOTOXICITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG USE; HEMOLYSIS; HISTORY OF MEDICINE; HUMAN; INSECTICIDE RESISTANCE; LIVER TOXICITY; MALARIA; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0035153917     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.2.185     Document Type: Review

References (148)

1. Quinoline antimalarials
2. World Health Organization report on infectious diseases, removing obstacles to healthy development
3. The current global malaria situation
4. Malaria in the African highlands: Past, present and future
5. Resistance to dieldrin + fipronil assorts with chromosome inversion 2La in the malaria vector Anopheles gambiae
6. Review of the prevalence of malaria in Zimbabwe with specific reference to parasite drug resistance (1984-96)
7. Drug resistance among malaria and other parasites
8. Mefloquine for malaria chemoprophylaxis 1992-1998: A review
9. Why is it that antimalarial drug treatments do not always work?
10. Pinocytic uptake and digestion of haemoglobin in malaria parasites
11. Haemoglobin metabolism in the malaria parasite Plasmodium falciparum
12. Plasmepsins I and II from the malarial parasite Plasmodium falciparum
13. Haemin lyses malaria parasites
14. The antibacterial activity of haemin compared with cobalt, zinc and magnesium protoporphyrin and its effect on potassium loss and ultrastructure of Staphylococcus aureus
15. The structure of malaria pigment (β-haematin)
16. Characterization of the products of the haem detoxification pathway in malarial late trophozoites by x-ray diffraction
17. An iron-carboxylate bond links the haem units of malaria pigment
18. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites
19. Haem polymerase. Modulation by chloroquine treatment of a rodent malaria
20. Control of haem polymerase by chloroquine and other quinoline derivatives
21. Malarial haemozoin/β-haematin supports haem polymerisation in the absence of protein
22. A comparison and analysis of several ways to promote haematin (haem) polymerisation and an assessment of its initiation in vitro
23. Haem polymerisation in malaria
24. Haem polymerisation in malaria
25. Plasmodium haemozoin formation mediated by histidine-rich proteins
26. Haem binding and polymerisation by Plasmodium falciparum histidine rich protein II: Influence of pH on activity and conformation
27. Spectroscopic characterization of the haem-binding sites in Plasmodium falciparum histidine-rich protein 2
28. The mechanism of β-haematin formation in acetate solution. Parallels between haemozoin formation and biomineralisation processes
29. Currently important antimalarial drugs
30. Relationship between antimalarial drug activity, accumulation and inhibition of haem polymerisation in Plasmodium falciparum in vitro
31. 4-Aminoquinoline resistance of Plasmodium falciparum: Insights from the study of amodiaquine uptake
32. A randomised trial of chloroquine, amodiaquine and pyrimethamine-sulfadoxine in Gambian children with uncomplicated malaria
33. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria
34. The bioactivation of amodiaquine by human polymorphonuclear leukocytes in vitro: Chemical mechanisms and the effects of fluorine substitution
35. Disposition of amodiaquine and related antimalarial agents in human neutrophils: Implications for drug design
36. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs
37. Effect of disposition of Mannich antimalarial agents on their pharmacology and toxicology
38. Amodiaquine-induced agranulocytosis: Drug inhibition of myeloid colonies in the presence of patients' serum
39. Amodiaquine-induced agranulocytosis: Inhibition of colony growth in bone marrow by antimalarial agents
40. Amodiaquine induced agranulocytosis and liver damage
41. Systematic review of amodiaquine treatment in uncomplicated malaria
42. Amodiaquine for treating malaria
43. The disposition of amodiaquine in man after oral administration
44. Quinidine in falciparum malaria
45. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand
46. Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure
47. Mefloquine-resistant falciparum malaria on the Thai-Burmese border
48. 8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit haematin polymerisation
49. Plasmodium vivax infections in US Army troops: Failure of primaquine to prevent relapse in studies from Somalia
50. Primaquine resistance in Plasmodium vivax
51. Pyronaridine: A new antimalarial drug
52. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa
53. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand
54. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children
55. The chemotherapy of rodent malaria. LVIII. Drug combinations to impede the selection of drug resistance, part 2: The new generation - Artemesinin or artesunate with long-acting blood schizontocides
56. Human malaria parasites in continuous culture
57. Ultrastructure of in vitro cultured exoerythrocytic stage of Plasmodium berghei in a hepatoma cell line
58. Chloroquine: Mechanism of drug action and resistance in Plasmodium falciparum
59. Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents
60. The role of haem in the activity of chloroquine and related antimalarial drugs
61. The interaction of chloroquine with nucleic acids and nucleoproteins
62. Chloroquine inhibits haem-dependent protein synthesis in Plasmodium falciparum
63. Plasmodium chabaudi-infection of mice: Effects of chloroquine and mefloquine. Inhibition of ornithine decarboxylase activity
64. Incorporation of radioactive precursors into Plasmodium berghei in vitro
65. The ribosomes of the simian malaria Plasmodium knowlesi. II. A cell-free protein synthesising system
66. In vitro studies on the mode of action of quassinoids with activity against chloroquine resistant Plasmodium falciparum
67. Lysosomes, pH and the anti-malarial action of chloroquine
68. An ultrastructural study of the effects of mefloquine on malaria parasites
69. Ultrastructure of Plasmodium falciparum in vitro. II. Morphological patterns of different quinolines' effects
70. The chemotherapy of rodent malaria. XXVII. Studies on mefloquine (WR142490)
71. Morphological effects of chloroquine on Plasmodium berghei in mice
72. Mode of action of chloroquine on Plasmodium berghei and P. cynomolgi
73. Quinoline-containing antimalarials - Mode of action, drug resistance and its reversal
74. Peptidases from Plasmodium falciparum cultured in vitro
75. Antimalarials increase vesicle pH in Plasmodium falciparum
76. Susceptibility of human malaria parasites to chloroquine is pH dependent
77. Alkalinisation of the food vacuole of malaria parasites by quinoline drugs and alkylamines is not correlated with their antimalarial activity
78. The effects of chloroquine and verapamil on digestive vacuolar pH of P. falciparum either sensitive or resistant to chloroquine
79. Complex formation between chloroquine and ferrihaemic acid in vitro and its effects on the antimalarial action of chloroquine
80. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites
81. Expression and characterisation of plasmepsin I from Plasmodium falciparum
82. Central role of haemoglobin degradation in mechansims of action of 4-aminoquinolines, quinoline methanols and phenanthrene methanols
83. Access to haematin: The basis of chloroquine resistance
84. Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum
85. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials
86. Characterization of chloroquine-haematin mu-oxo dimer binding by isothermal titration calorimetry
87. Thermodynamic factors controlling the interaction of quinoline antimalarial drugs with ferriprotoporphyrin IX
88. Characterisation of synthetic β-haematin and effects of the antimalarial drugs quinidine, halofantrine, desbutylhalofantrine and mefloquine on its formation
89. A nuclear magnetic resonance study of the interactions of antimalarial drugs with porphyrins
90. UV-visible and carbon NMR studies of chloroquine binding to urohaemin I chloride and uroporphyrin I in aqueous solutions
91. The iron-environment in haem and haem-antimalarial complexes of pharmacological interest
92. The chemical basis for the ferriprotoporphyrin IX-chloroquine induced lipid peroxidation
93. Inhibition of glutathione-dependent degradation of haem by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action
94. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials
95. Quinoline anti-malarial drugs inhibit spontaneous formation of β-haematin (malaria pigment)
96. On the molecular mechanism of chloroquine's antimalarial action
97. A common mechanism for blockade of haem polymerisation by antimalarial quinolines
98. A microtitre-based method for measuring the haem polymerisation inhibitory activity (HPIA) of antimalarial drugs
99. Structure-function relationships in aminoquinolines: Effect of amino and chloro groups on quinoline-haematin complex formation, inhibition of β-haematin formation and antiplasmodial activity
100. Structural specificity of chloroquine-haematin binding related to inhibition of haematin polymerisation and parasite growth
101. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro
102. Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines
103. Synthesis, antimalarial activity and molecular modelling of tebuquine analogues
104. New 4-aminoquinoline Mannich base antimalarials. 1. Effect of an alkyl substituent in the 5′-position of the 4′-hydroxyanilino side chain
105. New quinoline di-Mannich base compounds with greater antimalarial activity than chloroquine, amodiaquine or pyronaridine
106. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue
107. New amine and urea analogs of ferrochloroquine: Synthesis, antimalarial activity in vitro and electrochemical studies
108. Bisquinoline antimalarials: Their role in malaria chemotherapy
109. Synthesis and activity of some antimalarial bisquinolines
110. Haem detoxification by an insect
111. Haemozoin formation in the midgut of the blood sucking insect Rhodnius prolixus
112. Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum
113. UV-visible and carbon NMR studies of quinine binding to urohaemin I chloride and uroporphyrin I in aqueous solutions
114. The interaction of the haem-octapeptide, N-acetylmicroperoxidase-8 with antimalarial drugs: Solution studies and modelling by molecular mechanics methods
115. Antimalarial agents: Mechanism of action
116. Chloroquine resistance in malaria: A deficiency of chloroquine binding
117. Chloroquine-resistant Plasmodium falciparum: Effect of substrate on chloroquine and amodiaquin accumulation
118. Role for the Plasmodium falciparum digestive vacuole in chloroquine resistance
119. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil
120. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum
121. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum
122. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa
123. Assessment of the association between three pfmdr1 point mutations and chloroquine resistance in vitro of Malaysian Plasmodium falciparum isolates
124. Guinea Bissau: Association of chloroquine resistance of Plasmodium falciparum with the Tyr 86 allele of the multidrug resistance gene pfmdr1
125. Selection for the tyrosine-86 mutation of the pfmdr1 gene of Plasmodium falciparum by chloroquine and amodiaquine
126. Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross
127. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine
128. A strong association between mefloquine and halofantrine resistance and amplification, overexpression and mutation in the P-glycoprotein gene homologue (pfmdr) of Plasmodium falciparum in vitro
129. Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand
130. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemesinin
131. Allelic modifications of the cg2 and cg1 genes do not alter the chloroquine response of drug-resistant Plasmodium falciparum
132. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance
133. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance
134. Identification of a chloroquine importer in Plasmodium falciparum: Differences in import kinetics are genetically linked with a chloroquine-resistant phenotype
135. + exchanger determines chloroquine uptake in Plasmodium falciparum
136. Chloroquine uptake, altered partitioning and the basis of drug resistance: Evidence for chloride-dependent ionic regulation
137. Digestive vacuolar pH of intact intraerythrocytic P. falciparum either sensitive or resistant to chloroquine
138. 6
139. Antimalarial drug resistance and combination chemotherapy
140. Delaying antimalarial drug resistance with combination chemotherapy
141. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria
142. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria - A systematic review
143. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria
144. The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance, part 1. Which model is appropriate?
145. 4-Aminoquinoline analogues of chloroquine with shortened side-chains retain activity against chloroquine resistant Plasmodium falciparum
146. What role can public health institutions play in drug development for the poor? A case study of artesunate